MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation

AI Briefing

• – MinervaX strengthens its executive leadership team with Jamila Louahed as CDO and Hans Henrik Chrois Christensen as CFO, bringing late-stage development, global regulatory, and operational expertise as the company advances its GBS vaccine towards pivotal trial initiation.
• – The appointments build on robust Phase II results, paving the way for a registrational trial and meeting the urgent global need for a GBS vaccine.
• – The company's CEO, Per Fischer, welcomed the new additions, stating that Jamila and Hans Henrik join at an important moment for the company as it prepares for pivotal trial initiation.